LSNE gets European foothold with deal for sterile drug facility

LSNE lyophilization vials
CDMO Lyophilization Services of New England has added a European facility with the buyout of a sterile drug site in Spain. (LSNE)

Lyophilization Services of New England (LSNE) already has four facilities in the U.S., but it has now jumped the Atlantic to pick up its first location in Europe.

The Bedford, New Hampshire-based CDMO has completed a deal for a sterile drug manufacturing facility in Leon, Spain, it announced Monday. Terms of the deal were not disclosed by LSNE but in am email a spokeswoman said the plant with 87 employees was acquired from AMRI. 

“Acquiring this high quality facility in León was the logical next step in our growth strategy given our strong and growing client base in Europe,” said Matthew Halvorsen, CEO at lyophilization specialist LSNE.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Private equity fund buys out sterile injectables maker LSNE 

The CDMO, which is owned by private equity firm Permira, has three facilities in New Hampshire and one in Wisconsin.

The company said that the facility recently completed an FDA inspection as well as one by authorities in Spain so can serve both the U.S. and European markets.

The facility includes four high-speed aseptic fill lines and commercial-scale lyophilization so can handle both clinical and commercial products, according to LSNE. The acquisition also adds prefilled syringe, ophthalmic and sterile bulk lyophilization capabilities to the company.

LSNE said it intends for the new facility “to focus on pharmaceutical products that have complex requirements such as emulsions, suspensions, liposomal formulations and nanoparticle products.”

This is the second deal for LSNE since Permira bought it in 2017. Last year, it picked up from PSC Biotech a 37,000-square-foot aseptic fill-finish manufacturing facility in Madison, Wisconsin, that produces clinical supply.

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.